Latest Breaking News On - Centessa pharmaceuticals doses first - Page 1 : comparemela.com

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

United statesCity ofUnited kingdomPalladio biosciencesJohn frauncesSaurabh sahaCentessa pharmaceuticals doses firstPalladio biosciences incCentessa pharmaceuticalsCentessa pharmaceuticals doses first subjectGlobal phaseAutosomal dominant polycystic kidneyAutosomal dominant polycystic kidney diseaseNew drug applicationChief executive officerMayo clinic